z-logo
open-access-imgOpen Access
Pioglitazone Rapidly Increases Serum Adiponectin Levels in Men With Normal Glucose Tolerance
Author(s) -
Yukio Ikeda,
Hiroshi Takata,
Kosuke Inoue,
Masayuki Shinahara,
Shojiro Inada,
Hiroshi Maruyama,
Fumiaki Osaki,
Tadashi Suehiro,
Kozo Hashimoto
Publication year - 2007
Publication title -
diabetes care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.636
H-Index - 363
eISSN - 1935-5548
pISSN - 0149-5992
DOI - 10.2337/dc07-0308
Subject(s) - pioglitazone , adiponectin , thiazolidinedione , medicine , endocrinology , diabetes mellitus , type 2 diabetes , insulin resistance
The thiazolidinedione class of antidiabetes drugs has various pleiotropic effects on cardiovascular diseases and lipid metabolism (1). Thiazolidinediones including pioglitazone have been shown to increase circulating adiponectin in diabetic subjects, although the mechanism is not well understood (2,3). Since, in previous studies, adiponectin levels in diabetic patients were evaluated after ≥3 weeks of pioglitazone treatment, elevated adiponectin may be, in part, secondary to improved lipid and glucose handling in these studies. In this study, we examined short-term effects of pioglitazone on serum adiponectin in nondiabetic subjects to assess the effect of pioglitazone independently of glycolipid …

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom